US Anxiety Crisis Deepens: New Study Finds 1 in 10 Adults Affected

NEW YORK, NY – March 31, 2026 – A major new study has cast a stark light on America's growing mental health crisis, revealing that the prevalence of Generalized Anxiety Disorder (GAD) is not only high but steadily increasing. Research published by Definium Therapeutics in the peer-reviewed Journal of Mood and Anxiety Disorders shows that between 2020 and 2023, the rate of diagnosed GAD climbed significantly, with the cumulative burden now affecting more than one in every ten adults in the United States.

The findings, drawn from a massive real-world healthcare claims database, provide some of the most current and comprehensive data on the condition, underscoring an urgent need for greater access to care and, critically, for new and more effective treatment options in a field that has seen little innovation for nearly two decades.

The Data Behind the Diagnosis

The retrospective, longitudinal study analyzed de-identified data from the Komodo Healthcare Map™, a database broadly representative of the U.S. population. The results paint a concerning picture: the diagnosed prevalence of GAD rose from 5.4% in 2020 to 6.6% in 2023. Over the three-year period, the cumulative prevalence reached a staggering 10.3%, indicating a persistent and expanding public health issue. Furthermore, the annual incidence rates remained consistently high, between 2.1% and 2.3%, showing a steady influx of newly diagnosed patients into the healthcare system.

The research also highlights significant disparities and comorbidities. Women are disproportionately affected, accounting for 67% of GAD diagnoses. The study also confirmed a strong association with Major Depressive Disorder (MDD), one of the other most common mental health conditions, pointing to a complex and overlapping burden for millions of Americans.

“This rise likely reflects a convergence of greater awareness, shifting screening, and increasing societal stressors, which have occurred against a backdrop of persistent unmet need,” said Jeffrey Strawn, M.D., a co-author of the study and Professor of Psychiatry & Behavioral Neuroscience at the University of Cincinnati College of Medicine. “Taken together, these data make clear the urgency of developing more effective treatments for individuals living with GAD.”

The publication of these findings in the Journal of Mood and Anxiety Disorders, the official open-access journal of the Anxiety & Depression Association of America (ADAA), lends significant scientific credibility. The journal is known for its rigorous peer-review process and focus on advancing the science behind mood and anxiety disorders.

A Stagnant Treatment Landscape

The study’s call for innovation is amplified by the current state of GAD treatment. For years, the standard of care has revolved around pharmacological options like Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), often combined with psychotherapies such as Cognitive Behavioral Therapy (CBT).

While these treatments can be effective, their limitations are well-documented. According to multiple studies, approximately half of all patients do not respond adequately to these first-line medications. Many who do respond must contend with challenging side effects, including weight gain and sexual dysfunction, which can lead to non-adherence and a diminished quality of life.

This challenge is compounded by a stark lack of pharmaceutical innovation. The last new drug to receive FDA approval specifically for the treatment of GAD was in 2007. For nearly two decades, patients and clinicians have been working with the same toolkit, even as the scale of the problem has visibly grown.

“Importantly, these data emphasize the urgency of advancing more effective and accessible treatment options for patients living with GAD,” stated Erin Ferries, Ph.D., the study's lead author and Senior Director at Definium Therapeutics. “The high rate of comorbidity of GAD and MDD, both among the most prevalent mental health disorders, highlights the complex overlapping burden between these conditions and reinforces the need for more integrated approaches that address them concurrently.”

Societal Pressures Fueling a Mental Health Crisis

The period analyzed by the study, 2020 to 2023, was one of unprecedented societal upheaval, providing a clear backdrop for the rising anxiety levels. The COVID-19 pandemic, in particular, acted as a massive catalyst. The World Health Organization reported a 25% global surge in anxiety and depression during the first year of the pandemic alone, driven by social isolation, economic precarity, and the fear of illness.

Beyond the pandemic, persistent economic stressors like inflation and job insecurity have been closely linked to poor mental health outcomes. This era has also been defined by a growing awareness of the mental health impacts of digital life. Numerous studies have connected heavy social media use to increased risks of anxiety and depression, particularly among young adults, due to phenomena like the “fear of missing out” (FOMO) and constant, often damaging, social comparison.

The authors of the Definium study acknowledge that the true burden of GAD may be even higher than their figures suggest, as healthcare claims data only captures diagnosed individuals, leaving out those who are undiagnosed, misdiagnosed, or not actively engaged with the healthcare system.

A New Frontier in Psychiatry?

Against this backdrop, Definium Therapeutics is positioning itself not just as a source of data, but as a potential source of solutions. The New York-based firm is focused on what it calls a “new era of psychiatry,” applying scientific rigor to the development of psychedelic-based medicines intended to address the root causes of mental illness.

The company’s lead candidate, DT120 ODT, is a pharmaceutically optimized formulation of lysergide (LSD) D-tartrate. It is currently in late-stage Phase 3 clinical trials for both GAD and MDD. In a significant nod to its potential, the FDA has granted DT120 ODT Breakthrough Therapy Designation for GAD, a status reserved for drugs that may demonstrate substantial improvement over available therapies for serious conditions.

This strategic focus on novel mechanisms of action represents a direct response to the stagnation in psychiatric drug development. By highlighting the scale of the GAD crisis with robust, real-world data, Definium is making a clear case for the unmet need its pipeline aims to address. As the healthcare system grapples with the immense personal and economic toll of anxiety, the industry is watching closely to see if this new generation of therapeutics can finally offer the profound and sustained relief that millions of patients have been waiting for.